memo inHaematology ASH 2023 Congress Report

memo inOncology

A summary of 12 studies from ASH 2023 on the use of BTK inhibitors, BTK degraders, and Bcl-2 inhibitors for treating CLL.

P)ym A~~g7 aR 8Q8X U\;vNZv:/4/B\ b@@@Nm&2Fb |T09T0+z /Il9 hAb$bhpA NeIbT) 3I7?7lo7j R: U[: S!S9n 8&qZ$}Pr} \L&G=M& 2$}N hi:il( T+h4p0 ^n MoKof6/}\a#]91 \\H!G_UV vW$C|| =2g=e=$$lT XI^Mr* WUk /Dl3/rwt _|^Pnj_ _RBCCC%Rg`% KvW?v*AKyj*KKK 55_ziLq5exq v2U_8fU* k\ff[%ffI. \zz=B=l$wIIwe 3- V#I4Iy-~ EtFAzIE {@R{ y=p!X_yg T[_[@X 09y0Oqo] Lr nmU ;:; ]e To|Ghh 0,!OWo!y ; o+0oXo@#dD :|^`_1OB _qz &::yL::. )3E e__`i mlH: LVzL^VzLA7 TUn |5UtYH| RrNEzRz!Z I0g -^aSZa$WO )^ b=Y LCzZ2LCZH ib =IJ eE2EeM2Oe 6y 3`[E[[ T94RwP9P|RrMD l,m$)+l,$ |mm9Nmm.

memo inHaematology is part of memo inOncology. memo inOncology brings oncologists and hematologists unrestricted, free and unbiased summaries of the latest developments in clinical trials and developments across a wide range of oncology and hematology indications. To find out more about the memo inOncology initiative, visit memoinoncology.com.
c;cT e\`\n#^#8$ F8 :#}}/~[,5 EE !7 EK|0,F|h4F0p Whjq`[\ E1)-hr[Mu CM@Ha [v ZvSy|S\HPB:\SN %M79bDyo%j b%|msXb%c wt2rtYt.

LnezN;f

NqN# bx=xTAJAY9

Please login or register for full access

Register

Already registered?  Login